Seminoma staging

Revision as of 04:16, 29 April 2019 by Sogand (talk | contribs) (→‎Staging)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Seminoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Seminoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

TNM
Stage Grouping

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Treatment - Stage I
Treatment - Stage II
Treatment - Stage III
Treatment - Recurrent

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Seminoma staging On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Seminoma staging

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Seminoma staging

CDC on Seminoma staging

Seminoma staging in the news

Blogs on Seminoma staging

Directions to Hospitals Treating Seminoma

Risk calculators and risk factors for Seminoma staging

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]

Overview

According to the TNM classification and stage groupings, there are 3 stages of seminoma based on the size and extent of the primary tumor, number and location of any regional lymph nodes (abdominal retroperitoneal) infiltrated by tumor cells, distant metastasis, and serum tumor marker levels.

Staging

Stage TNM/S Description
Stage 0 pTisb Germ cell neoplasia in situ
N0 cNO No regional lymph node metastasis
N0 pNO No regional lymph node metastasis
M0 No distant metastasis
SO SO Marker study levels within normal limits
Stage I pT1 Tumor limited to testis (including rete testis invasion) without lymphovascular invasion.
pT1ab Tumor <3 cm in size
pT1bb Tumor ≥3 cm in size
pT2 Tumor limited to testis (including rete testis invasion) with lymphovascular invasion OR tumor invading hilar soft tissue or epididymis or penetrating visceral mesothelial layer covering the external surface of tunica albuginea with or without lymphovascular invasion.
pT3 Tumor directly invades spermatic cord soft tissue with or without lymphovascular invasion.
pT4 Tumor invades scrotum with or without lymphovascular invasion.
cNO No regional lymph node metastasis.
pNO No regional lymph node metastasis.
MO No distant metastasis.
SX Marker studies not available or not performed.
Stage IA pT1 Tumor limited to testis (including rete testis invasion) without lymphovascular invasion.
pT1aa Tumor <3 cm in size
pT1bb Tumor ≥3 cm in size
cNO No regional lymph node metastasis.
pNO No regional lymph node metastasis.
MO No distant metastasis.
S0 Marker study levels within normal limits.
Stage IB pT2 Tumor limited to testis (including rete testis invasion) with lymphovascular invasion OR tumor invading hilar soft tissue or epididymis or penetrating visceral mesothelial layer covering the external surface of tunica albuginea with or without lymphovascular invasion.
cN0 No regional lymph node metastasis
pN0 No regional lymph node metastasis
M0 No distant metastasis
S0 Marker study levels within normal limits.
pT3 Tumor directly invades spermatic cord soft tissue with or without lymphovascular invasion.
cN0 No regional lymph node metastasis
pN0 No regional lymph node metastasis
M0 No distant metastasis
S0 Marker study levels within normal limits.
pT4 Tumor invades scrotum with or without lymphovascular invasion.
cN0 No regional lymph node metastasis
pN0 No regional lymph node metastasis
M0 No distant metastasis
S0 Marker study levels within normal limits.
Stage IS pTX Primary tumor cannot be assessed.
pT0 No evidence of primary tumor.
pTis Germ cell neoplasia in situ.
pT1 Tumor limited to testis (including rete testis invasion) without lymphovascular invasion.
pT1ab Tumor 3 cm in size.
pT1bb Tumor ≥3 cm in size.
pT2 Tumor limited to testis (including rete testis invasion) with lymphovascular invasion OR tumor invading hilar soft tissue or epididymis or penetrating visceral mesothelial layer covering the external surface of tunica albuginea with or without lymphovascular invasion.
pT3 Tumor directly invades spermatic cord soft tissue with or without lymphovascular invasion.
pT4 Tumor invades scrotum with or without lymphovascular invasion.
cN0 No regional lymph node metastasis.
pN0 No regional lymph node metastasis.
M0 No distant metastasis
S1 LDH < 1.5 × Nc and hCG (mIU/mL) <5,000 and AFP (ng/mL) <1,000.
S2 LDH 1.5–10 × Nc or hCG (mIU/mL) 5,000–50,000 or AFP (ng/mL) 1,000–10,000.
S3 LDH > 10 × Nc or hCG (mIU/mL) >50,000 or AFP (ng/mL) >10,000.
Stage II Any pT/TX Primary tumor cannot be assessed/Marker studies not available or not performed.
cN1 Metastases with a lymph node mass ≤2 cm in greatest dimension OR multiple lymph nodes, none >2 cm in greatest dimension.
cN2 Metastasis with a lymph node mass >2 cm but ≤5 cm in greatest dimension OR multiple lymph nodes, any one mass >2 cm but ≤5 cm in greatest dimension.
cN3 Metastasis with a lymph node mass >5 cm in greatest dimension.
pN1 Metastasis with a lymph node mass ≤2 cm in greatest dimension and ≤5 nodes positive, none >2 cm in greatest dimension.
pN2 Metastasis with a lymph node mass >2 cm but ≤5 cm in greatest dimension; or >5 nodes positive, none >5 cm; or evidence of extranodal extension of tumor.
pN3 Metastasis with a lymph node mass >5 cm in greatest dimension.
M0 No distant metastases.
SX Marker studies not available or not performed.
Stage IIA Any pT/TX Primary tumor cannot be assessed/Marker studies not available or not performed.
cN1 Metastases with a lymph node mass ≤2 cm in greatest dimension OR multiple lymph nodes, none >2 cm in greatest dimension.
pN1 Metastasis with a lymph node mass ≤2 cm in greatest dimension and ≤5 nodes positive, none >2 cm in greatest dimension.
M0 No distant metastasis
S1 LDH < 1.5 × Nb and hCG (mIU/mL) <5,000 and AFP (ng/mL) <1,000.
Stage IIB Any pT/TX See above description.
cN2 Metastasis with a lymph node mass >2 cm but ≤5 cm in greatest dimension OR multiple lymph nodes, any one mass >2 cm but ≤5 cm in greatest dimension.
pN2 Metastasis with a lymph node mass >2 cm but ≤5 cm in greatest dimension; or >5 nodes positive, none >5 cm; or evidence of extranodal extension of tumor.
M0 No distant metastases.
S0 Marker study levels within normal limits.
pT/TX See above description
cN2 Metastasis with a lymph node mass >2 cm but ≤5 cm in greatest dimension OR multiple lymph nodes, any one mass >2 cm but ≤5 cm in greatest dimension.
pN2 Metastasis with a lymph node mass >2 cm but ≤5 cm in greatest dimension; or >5 nodes positive, none >5 cm; or evidence of extranodal extension of tumor.
M0 No distant metastases.
S1 LDH < 1.5 × Nb and hCG (mIU/mL) <5,000 and AFP (ng/mL) <1,000.
Stage IIC Any pT/TX See above description.
cN3 Metastasis with a lymph node mass >5 cm in greatest dimension.
pN3 Metastasis with a lymph node mass >5 cm in greatest dimension.
M0 No distant metastases.
S0 Marker study levels within normal limits.
Any pT/TX See above description.
cN3 Metastasis with a lymph node mass >5 cm in greatest dimension.
pN3 Metastasis with a lymph node mass >5 cm in greatest dimension.
M0 No distant metastasis
S1 LDH < 1.5 × Nb and hCG (mIU/mL) <5,000 and AFP (ng/mL) <1,000.
Stage III Any pT/TX See above description.
cNX Regional lymph nodes cannot be assessed.
cN0 No regional lymph node metastasis.
cN1 Metastases with a lymph node mass ≤2 cm in greatest dimension OR multiple lymph nodes, none >2 cm in greatest dimension.
cN2 Metastasis with a lymph node mass >2 cm but ≤5 cm in greatest dimension OR multiple lymph nodes, any one mass >2 cm but ≤5 cm in greatest dimension.
cN3 Metastasis with a lymph node mass >5 cm in greatest dimension.
pNX Regional lymph nodes cannot be assessed.
pN0 No regional lymph node metastasis.
pN1 Metastasis with a lymph node mass ≤2 cm in greatest dimension and ≤5 nodes positive, none >2 cm in greatest dimension.
pN2 Metastasis with a lymph node mass >2 cm but ≤5 cm in greatest dimension; or >5 nodes positive, none >5 cm; or evidence of extranodal extension of tumor.
pN3 Metastasis with a lymph node mass >5 cm in greatest dimension.
M1 Distant metastases.
M1a Nonretroperitoneal nodal or pulmonary metastases.
M1b Nonpulmonary visceral metastases.
SX Marker studies not available or not performed.
Stage IIIA Any pT/TX See above description.
Any N See descriptions in this table, Stage III.
M1a Nonretroperitoneal nodal or pulmonary metastases.
S0 Marker study levels within normal limits.
Any pT/TX See above description.
Any N See descriptions in this table, Stage III.
M1a Nonretroperitoneal nodal or pulmonary metastases.
S1 LDH < 1.5 × Nb and hCG (mIU/mL) <5,000 and AFP (ng/mL) <1,000.
Stage IIIB Any pT/TX See above descriptions
cN1 Metastases with a lymph node mass ≤2 cm in greatest dimension OR multiple lymph nodes, none >2 cm in greatest dimension.
cN2 Metastasis with a lymph node mass >2 cm but ≤5 cm in greatest dimension OR multiple lymph nodes, any one mass >2 cm but ≤5 cm in greatest dimension.
cN3 Metastasis with a lymph node mass >5 cm in greatest dimension.
pN1 Metastasis with a lymph node mass ≤2 cm in greatest dimension and ≤5 nodes positive, none >2 cm in greatest dimension.
pN2 Metastasis with a lymph node mass >2 cm but ≤5 cm in greatest dimension; or >5 nodes positive, none >5 cm; or evidence of extranodal extension of tumor.
pN3 Metastasis with a lymph node mass >5 cm in greatest dimension.
M0 No distant metastases.
S2 LDH 1.5–10 × Nb or hCG (mIU/mL) 5,000–50,000 or AFP (ng/mL) 1,000–10,000.
Any pT/TX See above descriptions
Any N See descriptions in this table, Stage III.
M1a Nonretroperitoneal nodal or pulmonary metastases.
S2 LDH 1.5–10 × Nb or hCG (mIU/mL) 5,000–50,000 or AFP (ng/mL) 1,000–10,000.
Stage IIIC Any pT/TX See above descriptions.
cN1 Metastases with a lymph node mass ≤2 cm in greatest dimension OR multiple lymph nodes, none >2 cm in greatest dimension.
cN2 Metastasis with a lymph node mass >2 cm but ≤5 cm in greatest dimension OR multiple lymph nodes, any one mass >2 cm but ≤5 cm in greatest dimension.
cN3 Metastasis with a lymph node mass >5 cm in greatest dimension.
pN1 Metastasis with a lymph node mass ≤2 cm in greatest dimension and ≤5 nodes positive, none >2 cm in greatest dimension.
pN2 Metastasis with a lymph node mass >2 cm but ≤5 cm in greatest dimension; or >5 nodes positive, none >5 cm; or evidence of extranodal extension of tumor.
pN3 Metastasis with a lymph node mass >5 cm in greatest dimension.
M0 No distant metastases.
S3 LDH > 10 × Nb or hCG (mIU/mL) >50,000 or AFP (ng/mL) >10,000.
Any pT/TX See above descriptions.
Any N See descriptions in this table, Stage III.
M1a Nonretroperitoneal nodal or pulmonary metastases.
S3 LDH > 10 × Nb or hCG (mIU/mL) >50,000 or AFP (ng/mL) >10,000.
Any pT/TX See above descriptions.
Any N See descriptions in this table, Stage III.
M1b Nonpulmonary visceral metastases.
SX Marker studies not available or not performed.
S0 Marker study levels within normal limits.
S1 LDH < 1.5 × Nb and hCG (mIU/mL) <5,000 and AFP (ng/mL) <1,000.
S2 DH 1.5–10 × Nb or hCG (mIU/mL) 5,000–50,000 or AFP (ng/mL) 1,000–10,000.
S3 LDH > 10 × Nb or hCG (mIU/mL) >50,000 or AFP (ng/mL) >10,000.

References

  1. "Testicular Cancer Treatment (PDQ®)—Health Professional Version - National Cancer Institute".

Template:WH Template:WS